GTC Biotherapeutics (fka GTCB)

[mblimon]

"In other words, the CD20 product will entail a different and more expensive kind of selling proposition than going head-to-head against either plasma-derived drugs or recombinant drugs such as NovoSeven that will no longer be actively detailed by the time GTC is in the market."

We may assume that DNA/BIIB's product will be in the market at least 4 years before LFB/GTCB's product comes to market, so the time for DNA?BIIB's product to become generic is not that long. On top of that, a substantially lower price is the best and cheapest promotion you can have, I would say.